Company
Racura Oncology Ltd
ASX:RAC
Racura Oncology (ASX: RAC) is a Phase 3 stage clinical biopharmaceutical company with a mission to silence cancer. Racura’s lead asset, (E,E)-bisantrene, is a small molecule anticancer agent that primarily functions via G4-DNA & RNA binding, leading to potent silencing of the important cancer growth regulator MYC. (E,E)-bisantrene has demonstrated therapeutic activity in cancer patients with a well characterised safety profile. Recent discoveries made by Racura have enabled composition of matter IP filings that provide for 20 years of patent protection over (E,E)-bisantrene. Racura Oncology is advancing a proprietary formulation of (E,E)-bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a Phase 3 clinical program in acute myeloid leukaemia (AML), a Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin, where we aim to deliver both cardioprotection and enhanced anticancer activity for solid tumour patients. Racura has collaborated with Astex, Emory University, Purdue University, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong, and University of Newcastle. Racura is actively exploring partnerships, licence agreements, or a commercial merger and acquisition to accelerate access to RC220 for patients with cancer across the world.
130 stories · page 5 of 7
Race Oncology receives positive guidance on Zantrene at pre-IND meeting with FDA; shares rise
FDA guidance provides a viable path for the clinical advancement of Zantrene in the US, once the company is ready to move on that market.
Race Oncology farewells CMO and appoints interim replacement ahead of recruitment process
The company has appointed Dr Ajay Duggal of Adnovate Clinical as interim CMO, pending the appointment of a new full-time CMO.
Race Oncology receives bull case valuation of A$6.1 billion in Pitt Street Research’s initiation report
The company is focused on the development of its key drug, Zantrene, which is being studied for preclinical and clinical efficacy in several cancer indications.
Race Oncology expands potential market with improved IV formulation for cancer drug Zantrene®
This improved formulation has greater market potential and is particularly well suited to solid tumour patients.
Race Oncology contracts Monash University's fragment-based screening program to help discover new FTO and ALKBH5 drugs
Professor Martin Scanlon of the Monash Fragment Platform will lead the project to discover new FTO and ALKBH5 inhibitors using the latest techniques in nuclear magnetic resonance spectroscopy.
The companies aiming to beat cancer serve up the highlights in the June quarter
Precedence Research suggests the global cancer therapeutics market size is predicted to surpass US$365.99 billion by 2030 and expand growth at a CAGR of 9.1% from 2022 to 2030.
Race Oncology fields data indicating Zantrene protects heart tissue from chemotherapy damage in mouse model, shares up
“This is the first evidence of its kind to demonstrate that there is a therapy that both targets the cancer and protects the heart," University of Newcastle associate professor Aaron Sverdlov said.